Intercron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Intercron

Property Description
Active ingredient Sodium Cromoglycate (Disodium cromoglycate)
Form Oral Solution, Capsules (for systemic use)
Pharmacological class Mast Cell Stabilizer, Anti-allergic Agent
Common use Prophylaxis of Allergic Reactions
Origin Synthetic (Chromone derivative)

Definition and Pharmacological Identity

Intercron is a synthetic, single-ingredient medicinal product containing the official active substance Sodium Cromoglycate, a chemical compound derived from the chromone structure. This substance is clinically recognized as a mast cell stabilizer and a prophylactic anti-allergic agent. Sodium Cromoglycate acts by inhibiting the release of chemical mediators from sensitized mast cells.

Its classification as a mast cell stabilizer is crucial, signifying that the medicine’s action is primarily preventive, distinguishing it from agents that only treat symptoms after an allergic reaction has started. The oral formulation is recognized as an intestinal anti-inflammatory agent, reflecting its specialized systemic focus for patients facing sensitivities.

Composition, Pharmaceutical Forms, and General Use

The composition of Intercron is defined by its sole active component, Sodium Cromoglycate, which is manufactured synthetically. While this substance is widely available in generic and other dosage forms (such as ophthalmic solutions), the Intercron brand is distinctively supplied as an oral solution or in capsules administered via the oral route. The oral solution is a key differentiating feature, often tailored for ease of administration in pediatric patient groups or individuals with swallowing difficulties.

These specific oral preparations are designed to act upon the mucosal lining of the gastrointestinal tract. The medicine's primary general purpose is to serve as a prophylactic agent, aiming to establish a cellular barrier within the digestive system to reduce the frequency and severity of immune responses when an individual anticipates exposure to sensitizing factors.

Regulatory References

  1. inhibiting the release of chemical mediators

What side effects are possible with Intercron?

Possible Side Effects and Safety Information

Intercron belongs to a class of antibiotics that is associated with a risk of serious, disabling, and potentially long-lasting or irreversible adverse reactions that can affect multiple body systems.

Serious Adverse Reactions (Boxed Warning Category)

The most significant safety concerns, highlighted by a strong regulatory warning, involve serious effects on the musculoskeletal, peripheral nervous, and central nervous systems, which may occur together in the same patient. These include:

  • Tendons, Muscles, and Joints: Tendinitis, tendon rupture (most commonly Achilles tendon), muscle pain, muscle weakness, and joint pain or swelling. The risk is higher in the elderly (over 60), patients with kidney disease, those with an organ transplant, or patients concurrently taking systemic corticosteroids.
  • Nerves: Peripheral neuropathy, characterized by a persistent feeling of pain, burning, tingling, numbness, or weakness in the arms or legs.
  • Central Nervous System (CNS) and Mental Health: Disturbances in attention, memory impairment, disorientation, agitation, nervousness, and serious psychiatric reactions such as depression, hallucinations, and suicidal thoughts.
  • Other Serious Risks: Significant blood sugar disturbances (hypoglycemia, potentially leading to coma), prolongation of the QT interval (a heart rhythm abnormality), and aortic aneurysm or dissection (rupture of the main artery).

Common Adverse Reactions

Commonly reported side effects include gastrointestinal issues such as nausea and diarrhea, as well as headache, dizziness, and difficulty sleeping.

Important Safety Notes

Regulatory agencies advise that Intercron should be avoided for less severe infections when other treatment options are available. If any sign of a serious adverse reaction occurs, such as tendon pain or symptoms of nerve damage, the medication should be stopped immediately. Treatment is contraindicated in patients who have experienced serious side effects from this class of antibiotics in the past.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Intercron (Sodium Cromoglycate) establish a profile of low acute toxicity concerning oral overdose. This assessment is directly related to the medicine’s limited systemic absorption across the digestive tract, resulting in a low likelihood of severe systemic exposure. Consequently, specific life-threatening outcomes or severe cardiovascular or neurological effects are not explicitly documented as direct consequences of acute oral over-ingestion.

In human cases, no specific symptoms have been reported that uniquely define an overdose. However, if an overdose is suspected, or if any symptoms manifest following the ingestion of an amount greater than prescribed, immediate medical attention is required.

Regulatory Mandated Actions

Official labeling consistently dictates that the management of a suspected overdose must include:

  • Contacting your regional poison control centre for specialized management instruction.
  • Medical observation as the primary procedural step, which is often sufficient due to the substance's low absorption.

Management focuses on general support, as no specific antidote is known for the effects of Sodium Cromoglycate overdose. If any symptoms appear during the observation period, symptomatic treatment is the officially required supportive measure. There are no population-specific considerations regarding increased severity documented within the official overdose sections.

Therapeutic Uses of Intercron

What Intercron Treats: Main Uses and Benefits

This medication is applied in situations involving certain distressing symptoms related to long-term viral infections and conditions characterized by abnormal cellular changes. It is commonly used in conditions such as chronic hepatitis B and C, certain lymphomas, and malignant melanomas.

Intercron helps address symptom clusters that may become intense or disruptive, such as systemic imbalance and symptoms that create noticeable physiological strain, which are often driven by the ongoing activity of the condition. It is relevant in contexts involving heightened systemic burden where symptoms may interfere with daily functioning. By supporting the body’s natural defense systems, it helps to reduce the activity of the virus and manage cellular changes.

The primary therapeutic benefit is to contribute to easing the overall symptom load and support the patient during difficult episodes. This therapeutic approach supports the management of chronic conditions by focusing on the patient's symptomatic experience. This focus assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with their conditions.

Quick Fact: Support for Symptoms related to Systemic Imbalance

It can be part of the management strategy for symptoms related to systemic imbalance, such as fatigue, in viral infections.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Intercron?

This section defines the officially documented population eligibility rules for Intercron (Oral Sodium Cromoglycate), as stated in governmental regulatory documents.


Populations Not Eligible (Contraindications)

Restriction Regulatory Wording
Hypersensitivity The medicine is contraindicated in patients with a known allergy to sodium cromoglycate or any excipient in the formulation.

Age-Based Eligibility

Age Group Regulatory Status
Adults and Adolescents Eligible (Use is established for those 12 years of age and older).
Children (< 2 years) Restricted Use. Safety and effectiveness have not been established. Use must be reserved for severe disease where the benefit clearly outweighs the risk.

Conditional Use and Special Populations

Use of Intercron requires caution or adjustment in specific physiological states:

  • Organ Function: Dosage should be decreased in patients with impaired renal or hepatic function due to the drug's excretion pathways.
  • Pregnancy/Lactation: Use during pregnancy is permitted only if clearly needed. Caution must be exercised during breastfeeding, as it is unknown if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Intercron (Sodium Cromoglycate oral) is characterized by a specific focus on restrictions rather than widespread drug–drug interactions, reflecting the medicine's limited systemic absorption. Official government labels do not document clinically significant pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, between Intercron and other medicinal products.


Official Regulatory Statements

Co-administration Restrictions: The oral solution must not be mixed with food, fruit juice, or milk. Co-administration with these liquids is formally prohibited in regulatory documentation, as it may prevent the medicine from working properly. A timing-based restriction is also mandated, requiring administration one-half hour prior to meals.

Non-Clinical Pharmacodynamic Finding: The US FDA label documents a non-clinical interaction finding with Isoproterenol. In specific animal models (pregnant mice), co-administration of high-dose subcutaneous cromolyn sodium and Isoproterenol resulted in an increased incidence of fetal malformations and resorptions.

Population-Specific Caution: Regulatory documents note that the effects of Intercron may be heightened in patients with impaired renal or hepatic function. This is due to the potential for reduced drug clearance, which can lead to increased systemic exposure.

Mechanism of Action

How Intercron Works

Intercron (sodium cromoglicate) acts through engagement mechanisms that primarily stabilize the membrane of mast cells. This molecular interaction modifies early intracellular steps, thereby reducing the influx of calcium ions across the mast cell membrane. Calcium mobilization is a requisite step for the activation and subsequent degranulation of these cells.

This molecular action, known as mast cell stabilization, interrupts the signaling sequences that culminate in the release of stored chemical mediators. By downregulating the secretion magnitude of potent signaling molecules, such as histamine and leukotrienes, Intercron modulates the signaling patterns of specific pathways involved in localized responses. This mechanism affects systems requiring targeted pathway adjustment and ultimately induces specific downstream physiological adjustments by sustaining the non-activated state of immune cells and limiting the local concentration of these inflammatory signals.

Dosage and Administration Information

How to Use Intercron

Intercron, which contains Sodium Cromoglycate, is administered through the oral route as a continuous, long-term prophylactic agent, meaning it must be taken regularly over an extended period. The effectiveness of the medication relies on consistent adherence to a fixed schedule rather than use on an as-needed basis, with full benefit typically achieved after two to six weeks of continuous use.


Official Administration Schedule

Intercron is generally prescribed to be taken four times daily (QID) at highly specific times. The approved schedule requires taking the dose approximately 15 to 30 minutes before each of the three main daily meals, followed by a final dose at bedtime.

Instruction Detail
Standard Adult Dose 200 mg four times daily (QID) initially.
Pediatric Dose (2–12 years) 100 mg four times daily initially.
Dose Adjustment Principle Dose may be increased (up to 400 mg QID) if symptom control is not adequate after 2–3 weeks, or gradually reduced to the minimum effective maintenance level.

Preparation and Procedural Constraints

The method of ingestion is defined by the formulation. The powder within the capsules may be swallowed whole, or it can be dissolved by mixing it with a small amount of hot water and then diluted with cold water. The contents of the oral solution ampules must be mixed with a glass of water before consumption. It is a procedural requirement that the medication is not mixed with fruit juice, milk, or food to maintain the integrity of the administration process.

Recent Clinical Evidence

Evidence for Use in Systemic Mast Cell Disorders

Research exploring Intercron’s evaluation in the context of systemic mast cell disorders primarily involved randomized, controlled clinical trials (RCTs). These studies typically included adults and adolescents with confirmed systemic mastocytosis. Using crossover designs, researchers examined how outcomes related to systemic imbalance changed when patients switched between the investigational agent and a placebo. Studies monitored patient-reported outcomes related to physical discomfort, specifically gastrointestinal symptoms (such as pain and diarrhea) and cutaneous symptoms (such as flushing). Due to the rarity of the condition, the sample sizes were limited in the available research.

Evidence for Use in Gastrointestinal Hypersensitivity

Intercron was evaluated in research exploring short-term symptom patterns in conditions associated with acute episodes, such as gastrointestinal hypersensitivity, which includes certain forms of Irritable Bowel Syndrome linked to food sensitivities. These studies primarily utilized double-blind, placebo-controlled cross-over trials. Studies explored outcomes related to systemic or functional imbalance by tracking the severity and frequency of symptoms, such as abdominal pain, bloating, and diarrhea. Findings were mixed across the reported studies; some randomized trials reported measured changes in outcomes, while others did not report differences in symptom patterns when compared to placebo.

Research Limitations and Uncertainty

Long-term effects are not fully established, as existing studies focus on defined time intervals, with most trials running for eight weeks or less. Research evaluated special patient populations, particularly children, but data for certain age groups and comorbidities remain insufficient. Overall, evidence quality varies across studies, and comparative evidence is lacking. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Intercron (FAQ)


Q: How is Intercron different from other similar treatments?

A: Official documents describe Intercron's active ingredient as a mast cell stabilizer, which prevents the release of certain chemical mediators that cause symptoms. This action classifies it as a prophylactic anti-allergic agent, indicating its intended use is for prevention rather than for treating symptoms once a reaction has fully begun.

Q: Does Intercron start working right away or does it take time?

A: Intercron is designed to be a preventive, or prophylactic, medication. Regulatory patient information indicates that the full beneficial effect is typically achieved only after the medicine has been taken continuously for a period of two to six weeks. Consistent adherence to the prescribed schedule is considered necessary to establish the full effect.

Q: How long does the effect of Intercron usually last?

A: Regulatory dosing information indicates that Intercron is prescribed to be taken four times daily (QID) at regular, frequent intervals. This frequent, scheduled administration is generally required to sustain the intended therapeutic effect.

Q: Are there certain foods I should avoid while using Intercron?

A: Official administration instructions emphasize taking Intercron before meals. It is also strictly mandated in the regulatory documents that the medication must not be mixed with food, fruit juice, or milk during consumption. This is formally prohibited as it may prevent the medicine from working properly.

Q: Does Intercron interact with common over-the-counter pain relievers?

A: Official government labels generally do not document clinically significant drug-drug interactions with other medicinal products, including common over-the-counter (OTC) pain relievers. This is related to the active substance's limited systemic absorption. However, informing a healthcare professional about all co-administered products remains standard practice.

Q: What happens if I drink alcohol while taking Intercron?

A: Regulatory patient guidance for Intercron’s active substance does not typically list a specific interaction with alcohol. However, patients should discuss alcohol consumption with a healthcare professional.

Q: What should I do if I miss taking Intercron?

A: Official patient guidance states that if a scheduled dose is missed, it should be taken as soon as it is remembered. However, if it is already almost time for the next scheduled dose, the missed dose should be skipped entirely. If a dose is skipped, official guidance states that doses must not be doubled to compensate.

Q: What should I do if a side effect seems serious?

A: Regulatory agencies advise that if any sign of a serious adverse reaction occurs, such as those listed in the official safety information (like tendon pain or nerve damage symptoms), the medication should be discontinued.

Q: Do I need to take Intercron with food?

A: No, the approved schedule requires Intercron to be taken approximately 15 to 30 minutes before each of the three main daily meals. Official administration requirements prohibit mixing the medication with food.

Q: Can Intercron be crushed or split?

A: Regulatory guidance defines the allowed methods of ingestion. The oral solution must be mixed with water, and the powder within the capsules may be dissolved in water or swallowed whole. Crushing or splitting the intact capsule shell is not a method of administration described in official instructions.

Q: Is Intercron safe for teenagers?

A: Age-based eligibility, as established in regulatory documents, indicates that the use of Intercron is established for Adults and Adolescents, which includes individuals 12 years of age and older.

Q: What is Intercron used for besides the main condition?

A: Official sources define Intercron's primary purpose as a prophylactic agent for certain systemic disorders. This includes its use in Systemic Mast Cell Disorders and for evaluating short-term symptom patterns in conditions like Gastrointestinal Hypersensitivity.

Q: Can I take Intercron with herbal supplements?

A: Official drug labels recommend that all patients inform their doctor about all products being taken. This recommendation covers prescription medicines, over-the-counter products, vitamins, and herbal supplements.

Q: Does Intercron interact with birth control pills?

A: Official regulatory labels do not document a specific interaction with oral contraceptives. To ensure comprehensive safety review, patients are always advised to inform their healthcare provider of all co-administered medications.

Q: How is the dose of Intercron usually decided?

A: Official guidelines provide a standard starting dose based on age (adults versus children). Following the initial period, the dose may be increased or gradually reduced over several weeks to determine the minimum effective maintenance level for the individual patient's condition.

Q: Is Intercron available as a generic version?

A: Yes, the active ingredient in Intercron, Sodium Cromoglycate, is available in generic versions, as confirmed by regulatory drug listings.

Q: Are there any specific lifestyle changes recommended while taking Intercron?

A: For patients using Intercron for conditions involving food sensitivities, patient guides emphasize following all advice regarding the avoidance of sensitizing foods. Beyond this, specific lifestyle requirements are typically determined by the underlying condition.

Q: Does Intercron have a high risk of drug dependency?

A: Regulatory documents do not mention physical dependence or abuse potential for Intercron, and the medicine is not classified as a controlled substance in the US.

Q: Is Intercron a blood thinner?

A: No, Intercron is classified as a Mast Cell Stabilizer and an Anti-allergic Agent. Its mechanism of action is related to inhibiting immune cell mediator release, and it does not directly affect blood clotting.

Q: Can Intercron affect my blood pressure?

A: Official safety information reports that low blood pressure has been reported as an occasional adverse reaction. Other cardiac effects, such as a fast heart rate (tachycardia), have also been occasionally reported.

Q: Are there different brand names for Intercron?

A: Yes, the active ingredient, Sodium Cromoglycate, is available under various brand names in different regions globally. Examples of other brand names include Gastrocrom and Nalcrom.

Q: Does Intercron interact with common cold or flu medicines?

A: Official regulatory labels state that there are no documented clinically significant pharmacokinetic interactions with other medicinal products. However, patients should always inform their doctor about all cold or flu medications they are taking, especially those that contain decongestants or pain relievers.

Q: Why is Intercron not recommended for people with a history of heart problems?

A: Due to the associated risk of QT interval prolongation (a heart rhythm abnormality), regulatory documents require caution for patients with certain pre-existing cardiac conditions.

Q: Can Intercron be taken with vitamins?

A: Official drug labels recommend that patients inform their doctor about all products being taken, including prescription medications, over-the-counter medicines, and vitamins.

Q: Is Intercron a controlled substance?

A: No, the active ingredient in Intercron, Sodium Cromoglycate, is not listed as a controlled substance by US regulatory authorities.

Q: What is the difference between Intercron and a placebo in clinical trials?

A: Research evidence from clinical trials is varied. Some trials reported measured changes in symptoms (like gastrointestinal pain and diarrhea) when Intercron was compared to a placebo. The evidence quality varies, as some trials reported measured changes in outcomes compared to placebo, while others did not find differences in symptom patterns.

How should Intercron be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Intercron are governed by official regulatory labeling to ensure product stability and environmental safety. These requirements are non-advisory and must be followed as stated.

Storage Conditions

Intercron (oral solution and capsules) must be kept at Controlled Room Temperature, typically between 20 C and 25 C, or below 30 C. The product requires protection from light and must remain in its original, tightly closed container or foil packaging until the time of use. It is a mandatory requirement to keep this and all medication out of the sight and reach of children.

Disposal Rules

Unused or expired Intercron must not be thrown away via household waste or flushed down the toilet (wastewater). Patients are instructed to return the medicine to a pharmacist or follow local official pharmaceutical take-back programs to ensure environmentally compliant disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intercron found in:

A-Z Index: